RCT to Investigate if Prostaglandin Analogue Drops Increase the Risk of Cystoid Macular Oedema After Cataract Surgery.
Status:
Completed
Trial end date:
2020-07-25
Target enrollment:
Participant gender:
Summary
Post-operative cystoid macular oedema (CMO) is a common complication causing visual loss
following routine cataract surgery. This complication is more prevalent in eyes with
excessive inflammation as they heal from surgery.
Prostaglandin analogues (PGA) are the commonest first line drugs used in the long-term
treatment of primary open angle glaucoma (POAG)- where they reduce the pathologically high
pressure in the eye. Prostaglandins are inflammatory mediators.
In the post-operative care of glaucoma patients undergoing cataract surgery, there is a
clinical dilemma whether to stop or continue the use of prostaglandin eye drops. Clinical
practice is completely dichotomized between continuing and stopping PGA treatment in the
postoperative period. There is conflicting scientific literature on the effect of PGA on the
incidence of CMO; and only a single randomized control trial (Miyake K, Arch Ophthalmol 1999,
117:34-40), where the post operative regime is not applicable to present practice, compared
the incidence of CMO following routine cataract surgery in POAG on PGA.